Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.
September 2016: The European Medicines Agency has reviewed idelalisib and the marketing authorisation has been updated.
For people taking idelalisib as a first therapy, the marketing authorisation now states that idelalisib is for ‘first-line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies’.
Additional information about infections has been included in the marketing authorisation.
Guidance development process
Next review date: September 2018
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.